title: Evaluation of patients' preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis.
abstract: OBJECTIVE
  To compare product attributes, preferences, and expected compliance associated with triamcinolone acetonide aqueous (TAA-AQ), fluticasone propionate (FP), and mometasone furoate (MF) nasal sprays in patients with allergic rhinitis.
  
  
  METHODS
  Data from 2 randomized, double-blind crossover studies with identical design were pooled (N = 215). Patients completed a 14-item sensory attributes questionnaire immediately after each product, and stated their preference and expected compliance with a prescription after receiving all products.
  
  
  RESULTS
  Compared with FP and MF, TAA-AQ was associated with significantly less odor and greater liking of odor ( P < 0.001); and less taste, less dryness of nose/throat, less aftertaste, and greater overall liking ( P < 0.05). Significantly more patients preferred most a prescription of TAA-AQ (50.0%) versus FP (25.0%; P < 0.001) and MF (25.0%; P < 0.001), and would "definitely comply" with TAA-AQ (62.5%) versus FP (49.0%; P < 0.01) and MF (51.0%; P < 0.01).
  
  
  CONCLUSIONS
  TAA-AQ was associated with significantly more positive sensory attributes, higher preference, and better expected compliance than FP and MF.
  
  
  CONCLUSIONS
  Patients' preferences for the sensory attributes of an intranasal corticosteroid may affect adherence to treatment.
authors.affiliation: Innovus Research Inc., Medford, MA, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Stokes
authors.forename: Stacey L
authors.initials: SL
authors.lastname: Amorosi
authors.forename: David
authors.initials: D
authors.lastname: Thompson
authors.forename: Leon
authors.initials: L
authors.lastname: Dupclay
authors.forename: Jorge
authors.initials: J
authors.lastname: Garcia
authors.forename: George
authors.initials: G
authors.lastname: Georges
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D000730:Androstadienes / Q000008:administration & dosage*; D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D005260:Female; D000068298:Fluticasone; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D009330:Nebulizers and Vaporizers; D010349:Patient Compliance; D017060:Patient Satisfaction; D011244:Pregnadienediols / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D011795:Surveys and Questionnaires; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*
chemical_list: D000730:Androstadienes; D018926:Anti-Allergic Agents; D005938:Glucocorticoids; D011244:Pregnadienediols; D000068656:Mometasone Furoate; D000068298:Fluticasone; D014222:Triamcinolone Acetonide